OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Liver Disease is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma	85
A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD	42
Critical Care Management of Acute-on-Chronic Liver Failure: Certainties and Unknowns	35
Liver Immunology, Immunotherapy, and Liver Cancers: Time for a Rethink?	34
Hepatic Extracellular Matrix and Its Role in the Regulation of Liver Phenotype	33
Genetic and Epigenetic Basis of Drug-Induced Liver Injury	29
Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease	28
HBV Biomarkers and Their Role in Guiding Treatment Decisions	27
Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease	27
Emerging Targets for the Treatment of Primary Sclerosing Cholangitis	23
Genetic Contributions to Biliary Atresia: A Developmental Cholangiopathy	21
Growth Hormone Signaling in Liver Diseases: Therapeutic Potentials and Controversies	20
Alcohol Plus Additional Risk Factors: Rodent Model of Liver Injury	19
Physiomimetic In Vitro Human Models for Viral Infection in the Liver	18
Role of YAP1 Signaling in Biliary Development, Repair, and Disease	17
Wilson Disease: Novel Diagnostic and Therapeutic Approaches	16
Mice Engrafted with Human Liver Cells	16
Diagnosis and Management of Early Stages of ALD	15
Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective	15
A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination	14
Circadian Regulation of Gene Expression and Metabolism in the Liver	14
	11
Role of Intestinal Barrier Disruption to Acute-on-Chronic Liver Failure	11
	10
Primary Cilia in Hepatic Biliary Hyperplasia: Implications for Liver Diseases	10

	10
To TIPS or Not to TIPS in High Risk of Variceal Rebleeding and Acute-on-Chronic Liver Failure	10
Role of Complement in Liver Diseases	10
Liver Neurobiology: Regulation of Liver Functions by the Nervous System	10
Novel Biomarkers of AKI in Cirrhosis	9
This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol	9
Endoscopic Advances in Hepatology	9
Patient-Centered Treatment of Cirrhosis	9
Combined Hepatocellular-Cholangiocarcinoma: A Clinical and Molecular Review	9
Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future	9
Management of Portal vein Thrombosis in Cirrhosis	9
Mesenchymal Stem Cell Transplantation in Liver Diseases	9
LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology	8
Pediatric and Adult Liver Disease in Alpha-1 Antitrypsin Deficiency	8
Big Data Analytics in Large Cohorts: Opportunities and Challenges for Research in Hepatology	8
Hepatocellular Carcinoma Chemoprevention with Generic Agents	8
Hepatitis Delta Infection: A Clinical Review	8
Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease	8
Erratum to: Genetic Contributions to Biliary Atresia: A Developmental Cholangiopathy	8
The Hepatic Porphyrias: Revealing the Complexities of a Rare Disease	8
Extracellular Vesicles and Micro-RNAs in Liver Disease	8
Advancements in MELD Score and Its Impact on Hepatology	7
Nonalcoholic Fatty Liver Disease: Current Global Burden	7
Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD	7
Screening for At-Risk Nonalcoholic Fatty Liver Disease in the Primary Care Setting	7
Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease?	6
Shared Mechanisms between Cardiovascular Disease and NAFLD	6
	6
Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	6
Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs	6
The Ways to Die: Cell Death in Liver Pathophysiology	6
Research Progress on the Role and Mechanism of IL-37 in Liver Diseases	6
Hepatic Innervations and Nonalcoholic Fatty Liver Disease	6
Alcohol-Metabolizing Enzymes, Liver Diseases and Cancer	6
	5
Gestational and Developmental Contributors of Pediatric MASLD	5
Immune Checkpoint Inhibitor-Induced Liver Injury	5
Influence of Sex in the Development of Liver Diseases	5
Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy	5
Role of Hepatocyte Nuclear Factor 4 Alpha in Liver Cancer	5
	5
	5
Mastering Core Recommendations during HEPAtology ROUNDS in Patients with Advanced Chronic Liver Disease	5
The Ploidy State as a Determinant of Hepatocyte Proliferation	5
Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research	5
Role of Neutrophils in the Development of Steatotic Liver Disease	5
Pathogenesis and Management of Intestinal Failure-Associated Liver Disease	5
Novel Endoscopic Bariatric Therapies for the Management of Nonalcoholic Steatohepatitis	4
Angiocrine Signaling in Sinusoidal Health and Disease	4
Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets	4

Preface (Introduction): Metabolic Liver Disease: A New Era in Hepatology	4
	4
	4
Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease	4
Microbial Modulation of the Gut–Liver Axis in Autoimmune Liver Diseases	4
MetALD: Genetic Factors and Clinical Outcomes	4
Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury	4
	4
The Molecular Pathogenesis of Sarcopenia/Frailty in Cirrhosis	4
Animal Models of Porphyria with Hepatic Involvement	4